Skip to main
AMED
AMED logo

Amedisys (AMED) Stock Forecast & Price Target

Amedisys (AMED) Analyst Ratings

Based on 25 analyst ratings
Hold
Strong Buy 8%
Buy 20%
Hold 64%
Sell 4%
Strong Sell 4%

Bulls say

Amedisys Inc. demonstrated a positive financial trajectory with consolidated revenues of $598.1 million for 4Q24, reflecting a year-over-year increase of 4.8%. The Home Health segment showed growth in total visits of 5.2%, while the High Acuity Care segment reported a significant revenue increase of 37.3% year-over-year, indicating strong demand for home-based healthcare services. Additionally, the Hospice segment saw a net revenue per day growth of 2.8%, supporting a favorable outlook amid trends in both Medicare and non-Medicare revenue growth.

Bears say

Amedisys Inc experienced a year-over-year decline in Medicare revenues of -3.9%, highlighting underlying challenges in its primary Home Health segment, which saw a modest revenue increase of 5.0% but a significant drop in adjusted EBITDA by -5.0%. The company's overall financial performance was further hindered by a -7.5% miss in consolidated adjusted EBITDA, alongside negative adjustments in both Home Health and Hospice segments that fell short of projections by -3% and -4%, respectively. Additionally, a contraction in Hospice segment metrics—despite revenue growth—indicates potential long-term operational pressure, as reflected by the decreasing EBITDA margins across both key segments.

Amedisys (AMED) has been analyzed by 25 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 20% recommend Buy, 64% suggest Holding, 4% advise Selling, and 4% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amedisys and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amedisys (AMED) Forecast

Analysts have given Amedisys (AMED) a Hold based on their latest research and market trends.

According to 25 analysts, Amedisys (AMED) has a Hold consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amedisys (AMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.